BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright

BioNTech (NASDAQ:BNTX) had its price target lowered by equities research analysts at HC Wainwright from $140.00 to $130.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 52.49% from the stock’s current price.

Several other research analysts also recently commented on BNTX. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Leerink Partners lowered BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a research note on Monday, February 2nd. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research note on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $133.07.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $85.25 on Tuesday. The company has a 50 day moving average of $103.23 and a 200 day moving average of $101.47. The stock has a market cap of $21.43 billion, a P/E ratio of -16.27 and a beta of 1.51. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01.

Institutional Trading of BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Dodge & Cox increased its stake in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the last quarter. GSK plc bought a new stake in BioNTech during the fourth quarter worth about $84,711,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of BioNTech by 344.4% in the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after purchasing an additional 444,332 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of BioNTech during the 4th quarter valued at about $41,656,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.